Partner Headlines - ARNA

  1. 5 New Biotech Developments Worth Watching

    Benzinga
  2. Morning Market Gainers

    Benzinga
  3. Benzinga's Top #PreMarket Gainers

    Benzinga
  4. Pharmacological Advancements in Neuroscience Drug Discovery & ...

    Benzinga
  5. Orexigen Soars On Obesity Drug's Surprise Health Boon

    IBD
  6. Morning Market Losers

    Benzinga
  7. Benzinga's Top #PreMarket Losers

    Benzinga
  8. 10 Stocks You Should Be Watching Today

    Benzinga
  9. Arena Pharmaceuticals Misses Q4 Expectations

    Benzinga
  10. Earnings Scheduled For March 2, 2015

    Benzinga
  11. CNBC's Stock Pops & Drops From January 21

    Benzinga
  12. Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following ...

    Benzinga
  13. 4 More Biotech Secondaries Traders Are Watching

    Benzinga
  14. Mid-Day Market Update: U.S. Stocks Surge; Netflix Shares Jump ...

    Benzinga
  15. Mid-Morning Market Update: Markets Mixed; UnitedHealth Profit ...

    Benzinga
  16. Morning Market Losers

    Benzinga
  17. Wednesday Morning Movers: Netflix Flying High

    Benzinga
  18. Arena Pharmaceuticals Announces Agreement to Sell Common Stock

    Benzinga
  19. Benzinga's Top #PreMarket Losers

    Benzinga
  20. Tuesday's After-Hours Movers: Netflix Leads The Pack

    Benzinga
  21. 5 Obesity Stocks Investors Are Watching

    Benzinga
  22. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  23. Mid-Afternoon Market Update: Dow Jumps Over 200 Points After ...

    Benzinga
  24. Mid-Day Market Update: J C Penney Jumps On Strong Holiday Sales; ...

    Benzinga
  25. Mid-Morning Market Update: Markets Surge; Monsanto Profit Tops ...

    Benzinga
  26. Morning Market Gainers

    Benzinga
  27. Benzinga's Top #PreMarket Gainers

    Benzinga
  28. 4 Potential Blockbuster Drugs The FDA Just Approved

    IBD
  29. Orexigen Therapeutics Gains On Diet Pill Nod From European Committee

    Benzinga
  30. Pharmaceutical Stocks In Play Following Merck/Cubist Deal

    Benzinga
  31. What's Driving Orexigen Therapeutics Higher?

    Benzinga
  32. Benzinga's Top #PreMarket Gainers

    Benzinga
  33. Arena Pharma Reports Q3 EPS Loss $0.05, Revenues Of $8.16M Vs. ...

    Benzinga
  34. Earnings Scheduled For November 3, 2014

    Benzinga
  35. 3 Pharma Companies Fighting Obesity

    Benzinga
  36. Benzinga's Top #PreMarket Gainers

    Benzinga
  37. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  38. Eisai And Arena Pharmaceuticals Announce Publication Of Pooled ...

    Benzinga
  39. Earnings Scheduled For August 1, 2014

    Benzinga
  40. Benzinga's Top #PreMarket Losers

    Benzinga
  41. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  42. Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His ...

    Benzinga
  43. Benzinga's Top #PreMarket Losers

    Benzinga
  44. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  45. FDA delays Orexigen drug

    IBD
  46. Is Arena Pharmaceuticals A Biotech Stock To Watch?

    Benzinga
  47. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  48. Orexigen Shares Plummet Following FDA Decision; Competition Gets ...

    Benzinga
  49. Arena Pharma Posts Q1 Loss Of $0.12/Share, Misses By ~$0.02/Share

    Benzinga
  50. Earnings Scheduled For May 12, 2014

    Benzinga
  51. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  52. Benzinga's Top #PreMarket Losers

    Benzinga
  53. Earnings Scheduled For February 27, 2014

    Benzinga
  54. Bad Earnings Weigh In On Diet Stocks

    Benzinga
  55. Top Trending Tickers On StockTwits For February 14

    Benzinga
  56. #PreMarket Primer: Friday, February 14: A Turnaround

    Benzinga
  57. Arena Pharmaceuticals Announces Filing for Marketing Authorization ...

    Benzinga
  58. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
  59. The Top Five Drug Launches Of 2013

    IBD
  60. (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance ...

    GuruFocus
  61. Benzinga's Top #PreMarket Gainers

    Benzinga
  62. Market Wrap For November 11: Relative Quiet as Traders and Investors ...

    Benzinga
  63. Market Wrap For November 8: Markets Erase Thursday's Losses; ...

    Benzinga
  64. Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement ...

    Benzinga
  65. Nasdaq Leads Stocks Lower; Twitter IPO Opens To 80% Gain

    IBD
  66. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  67. Benzinga's Top #PreMarket Losers

    Benzinga
  68. Market Wrap For Tuesday, October 15: Earnings Reports And White ...

    Benzinga
  69. Mid-Afternoon Market Update: Tumi Holdings Rises Amid Market ...

    Benzinga
  70. Mid-Morning Market Update: Markets Slip; Citigroup Profit Misses ...

    Benzinga
  71. UPDATE: Arena Says Eisai Will Double BELVIQ Sales Force to 4 ...

    Benzinga
  72. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and ...

    Benzinga
  73. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  74. Benzinga's Top Pre-Market Losers

    Benzinga
  75. Market Wrap For September 30: Debt Ceiling And Government Shutdown ...

    Benzinga
  76. Mid-Afternoon Market Update: Mellanox Rallies As Market Remains ...

    Benzinga
  77. Mid-Day Market Update: Dow Falls Over 100 Points; Active Network ...

    Benzinga
  78. Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net ...

    Benzinga
  79. UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following ...

    Benzinga
  80. Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing ...

    Benzinga
  81. Stocks Hitting 52-Week Lows

    Benzinga
  82. BMO Considers Recent Sales Data on Arena's Belviq, Maintains ...

    Benzinga
  83. CEO Shift Aside, Whose Weight-Loss Pill’s Ahead

    YCharts
  84. Stocks Hitting 52-Week Lows

    Benzinga
  85. Stocks Hitting 52-Week Lows

    Benzinga
  86. Arena Pharma Reports Closing of Phase 1b Clinical Trial for APD811

    Benzinga
  87. Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, ...

    Benzinga
  88. It's Hard to Sell a Pill That Nobody's Heard Of

    YCharts
  89. Weekly Preview: Earnings Season Continues, Fed In Focus, Economic ...

    Benzinga
  90. Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

    Benzinga
  91. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga
  92. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga
  93. Mid-Afternoon Market Update: Markets All Green, Research in Motion ...

    Benzinga
  94. Mid-Day Market Update: GenCorp Rises, Markets Erasing Losses

    Benzinga
  95. Mid-Morning Market Update: Verizon Misses Big on Earnings, Research ...

    Benzinga
  96. Vivus fell 4.2% to 13.72

    IBD
  97. Vivus Stock Drops On Downgrade; Rival Arena Rises

    IBD
  98. Measuring Social Network Buzz Over Pharma Stocks

    YCharts
  99. Vivus Stock Jumps On Latest Qsymia Shipment Numbers

    IBD
  100. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga
Trading Center